Level Biotechnology Inc. (TPEX:3118)
28.40
-0.50 (-1.73%)
Nov 20, 2026, 1:15 PM CST
Level Biotechnology Revenue
Level Biotechnology had revenue of 186.06M TWD in the quarter ending September 30, 2026, a decrease of -7.03%. This brings the company's total for the last twelve months to 695.30M, down -7.70% year-over-year. In the year 2025, Level Biotechnology had annual revenue of 736.59M with 0.72% growth. That makes Level Biotechnology the 33,592nd largest company in the world by revenue and 1,736th in Taiwan.
Revenue (ttm)
695.30M
Revenue Growth
-7.70%
P/S Ratio
1.33
Revenue / Employee
5.43M
Employees
128
Market Cap
921.66M
Revenue by Segment
- Reagent Consumable Materials Trading 370.01M 50.2%
- Instrument and Equipment Trading 239.73M 32.5%
- Entrusted Biotechnology Service Sales 126.86M 17.2%
Fiscal year ended Dec 31, 2025 See the full Level Biotechnology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 736.59M | 5.25M | 0.72% |
| Dec 31, 2024 | 731.35M | 70.74M | 10.71% |
| Dec 31, 2023 | 660.61M | 67.60M | 11.40% |
| Dec 31, 2022 | 593.01M | -84.27M | -12.44% |
| Dec 31, 2021 | 677.28M | 4.79M | 0.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Meribank Biotech | 408.48M |
| Abnova (Taiwan) | 337.63M |
| NeoCore Technology | 271.62M |
| TCI GENE | 251.39M |
| GeneReach Biotechnology | 241.13M |
| Lukas Biomedical | 170.01M |
| Enimmune | 53.45M |
| Holy Stone Healthcare | 47.51M |